Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 10/20 | 0.68 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539456 | 0.95 | QPCT (0.74) | QPCTQPCTLCDC7DBF4IP6K1 | |
| SCHEMBL2540844 | 0.91 | QPCT (0.83) | QPCTQPCTLLMNAIP6K1ALDH1A1 | |
| SCHEMBL2546370 | 0.91 | QPCT (0.83) | QPCTQPCTLCDC7DBF4IP6K1 | |
| SCHEMBL2537533 | 0.91 | QPCT (0.83) | QPCTQPCTLCDC7DBF4LMNA | |
| SCHEMBL2540194 | 0.89 | QPCT (0.67) | QPCTQPCTLCDC7DBF4LMNA | |
| SCHEMBL2545065 | 0.88 | QPCT (0.65) | QPCTQPCTLCDC7DBF4LMNA | |
| SCHEMBL2546623 | 0.87 | QPCT (0.64) | QPCTQPCTLCDC7DBF4IP6K1 | |
| SCHEMBL2543438 | 0.87 | QPCT (0.61) | QPCTQPCTL | |
| SCHEMBL2540846 | 0.87 | QPCT (0.64) | QPCTQPCTLCDC7DBF4MAPT | |
| SCHEMBL2546379 | 0.87 | QPCT (0.84) | QPCTQPCTLLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | claimed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | claimed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885QPCTL 8/4885CDC7 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.